MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer.
about
Accuracy Evaluation of a 3D Ultrasound-guided Biopsy System"MRI Stealth" robot for prostate interventions.In vivo (1)H MRS and (31)P MRSI of the response to cyclocreatine in transgenic mouse liver expressing creatine kinase.Quantification of metabolite concentrations in benign and malignant prostate tissues using 3D proton MR spectroscopic imaging.Treatment planning using MRI data: an analysis of the dose calculation accuracy for different treatment regionsIncremental value of magnetic resonance imaging in the advanced management of prostate cancer.Prostate MRI and 3D MR spectroscopy: how we do itProstate cancer patients' refusal of cancer-directed surgery: a statewide analysis.Spectral characterization of tissues in high spectral and spatial resolution MR images: Implications for a classification-based synthetic CT algorithm.GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRIMagnetic resonance imaging for prostate cancer clinical applicationFocal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI.A retrospective study of prostate cancer cases mimicking urothelial cell carcinoma of the bladder.Image-Guided High-Dose-Rate (HDR) Boost Localization Using MRI/MR Spectroscopy: A Correlation Study with Biopsy.Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.Systematisation of spatial uncertainties for comparison between a MR and a CT-based radiotherapy workflow for prostate treatmentsImaging in prostate cancer staging: present role and future perspectives.Role of MRI in prostate cancer detection.Clinical applications of spectral molecular imaging: potential and challenges.Early diagnosis of prostate cancer by citrate determination in urine with europium-oxytetracycline complex.The accuracy of magnetic resonance imaging in radical prostatectomyOutcome of Prostate Biopsy in Men Younger than 40 Years of Age with High Prostate-Specific Antigen (PSA) Levels.High-risk prostate cancer: value of multi-modality 3T MRI-guided biopsies after previous negative biopsies.PET-directed, 3D Ultrasound-guided prostate biopsy.Evaluating organ delineation, dose calculation and daily localization in an open-MRI simulation workflow for prostate cancer patients.Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).Practical aspects of prostate MRI: hardware and software considerations, protocols, and patient preparation.Molecular imaging and fusion targeted biopsy of the prostate.Mesoporous carbon nanomaterials in drug delivery and biomedical application.Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI.Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.Computer-aided diagnosis of prostate cancer with MRITowards the potential use of 1H NMR spectroscopy in urine samples for prostate cancer detection
P2860
Q30445213-930A7192-4C9D-4F86-9306-727D7DB1738FQ30500803-A87C827D-845F-49DA-9682-3583B24A689CQ31003888-24CB5AD9-278B-46E0-AC90-585906ACA681Q31123327-65098235-AC67-4EFC-B2FA-BC76C362EB07Q33621996-87CBC869-7093-471A-9EE3-A3BBDDA84DE4Q33772524-0D273CDB-7536-4B27-B61F-728EDD2EF321Q33954515-158CD2A1-FB4C-43CC-9740-8442EEBA078DQ35564143-C52A7824-CAC8-4C13-A899-7B61CEF4DA4CQ36290654-5DBB9E5F-E61F-423F-AC4F-E9F0AAF52128Q36291569-458A5732-4739-40F9-AFE2-19A4BA7DE26BQ36767668-082AAFF6-531F-4F84-81D1-57907753F701Q36837246-728FF095-E82D-40C2-BEEE-DCD7C2CBBC80Q37365428-EA23B08F-B94E-47AE-8F8D-686C3C2D2044Q37368378-5FC80D68-8C9B-4607-B47E-5A0ED5EA1FBCQ37401554-C3144255-D4B7-4253-B141-372536322F76Q37634144-77F0F3CA-7767-4E8D-987F-00CD145C1618Q37979650-98B44AB7-BA81-4F47-86E6-36F874FE5748Q38089710-922471E3-D291-465A-A927-49310B532E96Q38182512-5107C05D-9E71-4869-A595-73DFDE119E7AQ39313646-2366BE13-CC58-4135-BBF7-C1BE8E34483FQ39499962-610158AF-6B73-426A-A4C0-055B61CC17DBQ39929949-DF04AA55-8DBC-4826-A12B-32EC4F9887C6Q42001579-0CEC5733-D54E-43B3-BB1C-ADC413A414A4Q42991361-6F7ADFBE-3B5E-4A36-9C2E-45F7156EEEE9Q43162154-796C7296-8BDA-4ACC-A83C-EB1207A564F3Q43287327-141F2817-9106-4500-B090-60C62D32F920Q45568949-107A71BD-3087-4047-80BE-A920D007F4B8Q46567823-AF800124-7F8A-4F2E-8B32-171F91D57598Q47608215-C9D15102-9613-437F-A04A-9ABCF28AFCB7Q47846969-B7EDB655-A536-4BAC-82A9-E3EE94282E4EQ47955825-8036C07C-1CDE-4CC7-A80B-E71DA9C3F106Q53192471-0A6171D3-E2FA-456E-A72B-B32A8783529DQ57116404-EE7D86D8-286E-41C5-8B63-4EC9DDB898C8Q57401126-930219F1-4557-483D-99F8-73BD98414423
P2860
MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@ast
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@en
type
label
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@ast
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@en
prefLabel
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@ast
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@en
P2860
P356
P1476
MR imaging and MR spectroscopi ...... evaluation of prostate cancer.
@en
P2860
P304
P356
10.1259/BJR/11253478
P407
P478
78 Spec No 2
P577
2005-01-01T00:00:00Z